Robert LOUGHLIN and John Loughlin, Appellants, v. Renny Tse-Haw LING and Chun-Sheng Wu, Appellees.
No. 2011-1432.
United States Court of Appeals, Federal Circuit.
July 11, 2012.
1289
AFFIRMED IN PART, VACATED IN PART.
Glen M. Diehl, Diehl Servilla LLC, of Iselin, NJ, argued for appellant.
Todd R. Walters, Buchanan Ingersoll & Rooney P.C., of Alexandria, VA, argued for appellee. With him on the brief was Erin M. Dunston. Of counsel on the brief
Before RADER, Chief Judge, and LOURIE and MOORE, Circuit Judges.
LOURIE, Circuit Judge.
Robert Loughlin and John Loughlin (together, “Loughlin“) appeal from the judgment of the Board of Patent Appeals and Interferences (the “Board“) canceling claim 1 of U.S. Patent 7,434,426 (the “‘426 patent“) pursuant to their request for adverse judgment in light of the Board‘s decision on the relationship between
BACKGROUND
This appeal arises from an interference proceeding under
On May 13, 2004, Loughlin filed Application No. 10/845,624 (the “‘624 application“). The ‘624 application was published on November 18, 2004, as Publication No. 2004/0226324. On October 14, 2008, the ‘624 application issued as the ‘426 patent.
On February 5, 2007, Ling filed the ‘404 application, which was granted priority benefit under
In September 2010, the United States Patent and Trademark Office (“PTO“) declared an interference between claim 1 of Loughlin‘s ‘426 patent and claim 31 of Ling‘s ‘404 application. Shortly thereafter, Loughlin moved for judgment under
A claim which is the same as, or for the same or substantially the same subject matter as, a claim of an application published under section 122(b) of this title may be made in an application filed after the application is published only if the claim is made before 1 year after the date on which the application is published.
The Board denied Loughlin‘s motion. Loughlin v. Ling, Interference No. 105,766, slip op. at 7 (B.P.A.I. Feb. 17, 2011) (”Decision on Motion“). The Board concluded that the bar imposed by
On March 8, 2011, Loughlin requested adverse judgment under
DISCUSSION
In an appeal from the Board, we review factual findings for substantial evidence and legal conclusions, including statutory interpretation, de novo. Stevens v. Tamai, 366 F.3d 1325, 1330 (Fed. Cir. 2004). When interpreting a statute, “we give effect to the intent of Congress by ‘look[ing] not only to the particular statutory language, but to the design of the statute as a whole and to its object and policy.‘” In re Swanson, 540 F.3d 1368, 1375 (Fed. Cir. 2008) (alteration in original) (quoting Crandon v. United States, 494 U.S. 152, 158 (1990)).
*On September 16, 2011, the President signed into law the Leahy-Smith America Invents Act, Pub. L. No. 112-29, § 3(i), 125 Stat. 284, 289-90 (2011) (to be codified atLoughlin argues on appeal that the Board incorrectly determined that
In response, Ling argues that the Board correctly construed “an application filed” in
In the alternative, Ling contends that we should dismiss the appeal for lack of jurisdiction. According to Ling, Loughlin conceded priority by requesting entry of adverse judgment, so there was no final adverse decision from which Loughlin could appeal. Ling further contends that Loughlin failed to exhaust his administrative remedies by prematurely requesting adverse judgment. Finally, Ling asks us to dismiss Loughlin‘s appeal as an impermissible interlocutory appeal.
We first address Ling‘s jurisdictional arguments. “It is axiomatic that the initial inquiry in any appeal is whether the court to which appeal is taken has jurisdiction to hear the appeal.” Woodard v. Sage Prods., Inc., 818 F.2d 841, 844 (Fed. Cir. 1987) (en banc). Under
Appeals from interference actions are governed by
(b) Request for adverse judgment. A party may at any time in the proceeding request judgment against itself. Actions construed to be a request for adverse judgment include:
. . . .
(3) Concession of priority or unpatentability of the contested subject matter[.]
We conclude that the Board‘s decision on priority is a final, adverse judgment over which we have jurisdiction. Loughlin appropriately availed himself of Board
Ling‘s jurisdictional arguments rely primarily on two district court cases, Human Genome Sciences, Inc. v. Amgen, Inc., 552 F. Supp. 2d 466 (D. Del. 2008) (”HGS I“), and Human Genome Sciences, Inc. v. Genentech, Inc., 589 F. Supp. 2d 512 (D. Del. 2008) (”HGS II“). Those cases, however, do not compel the result sought by Ling. HGS I and HGS II were civil actions filed under
We now turn to the merits of Loughlin‘s appeal. We agree with Ling that the Board correctly interpreted
An application for patent for an invention disclosed in the manner provided by section 112(a) . . . in an application previously filed in the United States . . . shall have the same effect, as to such invention, as though filed on the date of the prior application. . . .
The broad applicability of
Loughlin offers no convincing reason why the priority benefit under
Loughlin argues that
Bolstering our conclusion is the fact that the Board has consistently interpreted “an application filed” in
Accordingly, the Board correctly interpreted “an application filed” in
CONCLUSION
We have considered Loughlin‘s remaining arguments and find them unpersuasive. The Board‘s judgment is affirmed.
AFFIRMED.
DYK
CIRCUIT JUDGE
